News
KPTI
1.880
+5.03%
0.090
Karyopharm Issues Convertible Preferred Stock, Alters Capital Structure
TipRanks · 2d ago
Weekly Report: what happened at KPTI last week (0907-0911)?
Weekly Report · 09/14 09:22
Karyopharm Faces Liquidity Crisis Under Forbearance Agreement
TipRanks · 09/11 12:18
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 09/11 12:06
Karyopharm, guarantors enter into forbearance agreement
TipRanks · 09/11 11:55
Karyopharm Therapeutics Signs Forbearance Agreement, Limited Waiver To Indentures For Additional Time To Advance Its Myelofibrosis Program; Did Not Pay $15.8M Due Under Sept. 10 Credit Agreement
Benzinga · 09/11 11:51
Weekly Report: what happened at KPTI last week (0831-0904)?
Weekly Report · 09/07 09:20
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Aug 2026
Seeking Alpha · 09/02 14:15
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), BioMarin Pharmaceutical (BMRN) and Karyopharm Therapeutics (KPTI)
TipRanks · 09/01 12:50
Karyopharm Submits SNDA For XPOVIO Plus Ruxolitinib In Myelofibrosis; Stock Up
NASDAQ · 08/31 13:06
Karyopharm Seeks Accelerated FDA Approval for XPOVIO Combo
TipRanks · 08/31 12:28
Karyopharm Submits SNDA Seeking Accelerated Approval For XPOVIO In Combination With Ruxolitinib
NASDAQ · 08/31 11:52
Karyopharm Therapeutics Submits sNDA To FDA Seeking Accelerated Approval For XPOVIO In Combination With Ruxolitinib For Patients With Myelofibrosis
Benzinga · 08/31 11:32
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
PR Newswire · 08/31 11:30
Weekly Report: what happened at KPTI last week (0824-0828)?
Weekly Report · 08/31 09:22
Karyopharm (KPTI) Earnings Call: Promise vs. Pressure
TipRanks · 08/26 00:07
Weekly Report: what happened at KPTI last week (0817-0821)?
Weekly Report · 08/24 09:22
Geron Corp: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis
Seeking Alpha · 08/18 13:58
Largest borrow rate increases among liquid names
TipRanks · 08/18 12:45
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Karyopharm Therapeutics (KPTI)
TipRanks · 08/18 02:10
More
Webull provides a variety of real-time KPTI stock news. You can receive the latest news about Karyopharm Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.